Following the recent share price fall, we are upgrading BTG to a Buy. While our conservative view on Varithena was borne out by the slow start last financial year, the long term potential from the other interventional therapies, such as TheraSphere, is attractive. BTG is a well managed, focused business targeting therapies in underserved areas. We believe that the current share price does not represent the long term potential for the business and with 12.9% upside to our 769p target price we are ....
11 Jun 2015
Upgrading to a Buy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Upgrading to a Buy
- Published:
11 Jun 2015 -
Author:
Elizabeth Klein -
Pages:
3
Following the recent share price fall, we are upgrading BTG to a Buy. While our conservative view on Varithena was borne out by the slow start last financial year, the long term potential from the other interventional therapies, such as TheraSphere, is attractive. BTG is a well managed, focused business targeting therapies in underserved areas. We believe that the current share price does not represent the long term potential for the business and with 12.9% upside to our 769p target price we are ....